Drug intelligence / Profile preview

anastrozole + pictilisib

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of anastrozole, an aromatase inhibitor, and pictilisib (GDC-0941), an oral inhibitor of multiple PI3K isoforms. This combination was investigated for its potential to overcome resistance to endocrine therapy in estrogen receptor-positive breast cancer by simultaneously targeting estrogen signaling and the PI3K pathway.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on anastrozole + pictilisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anastrozole + pictilisib.

Explore the full profile